Inhibitory KIR2DL2 receptor and HHV-8 in classic or endemic Kaposi sarcoma
- PMID: 35169985
- PMCID: PMC9939483
- DOI: 10.1007/s10238-022-00798-0
Inhibitory KIR2DL2 receptor and HHV-8 in classic or endemic Kaposi sarcoma
Abstract
KIR2DL2, an inhibitory Killer cell Immunoglobulin-like Receptor (KIR), has been shown to predispose to the development of several herpesvirus-associated diseases by inhibiting the efficiency of Natural Killer (NK) cells against virus-infected cells. The aim of this observational study was to assess the prevalence of KIR2DL2 and Human Herpes Virus 8 (HHV8) in patients affected with classical and endemic Kaposi sarcoma (KS), as well as in controls. Blood samples collected from 17 Caucasian, HIV-negative, immunocompetent patients affected with classical KS (c-KS), 12 African, HIV-negative patients with endemic KS (e-KS), 83 healthy subjects and 26 psoriatic patients were processed for genotypization by PCR for two KIR alleles, such as KIR2DL2 and KIR2DL3 and analyzed for HHV-8 presence. The totality of both c-KS and e-KS patients presented HHV-8 infection, whereas HHV8 was found in 26.9% of psoriatic subjects and 19.3% of healthy subjects. KIR2DL2 was found in the 76.5% of c-KS subjects, while the receptor was found in 41.7% of the e-KS group, 34.6% of psoriatic patients and 43.4% of healthy controls (p < 0.0001). A significantly higher prevalence of KIR2DL2 in c-KS patients than in all the other subjects was also confirmed comparing age-matched groups. Based on these results, the inhibitory KIR2DL2 genotype appears to be a possible cofactor which increases the risk of developing c-KS in HHV8-positive, immunocompetent subjects, while it seems less relevant in e-KS pathogenesis.
Keywords: HHV-8; KIR2DL2; Kaposi’s Sarcoma; Natural Killer (NK) cells.
© 2022. The Author(s).
Conflict of interest statement
None of the authors have any declaration of interest to report.
Figures


Similar articles
-
Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma.PLoS Pathog. 2012 Jan;8(1):e1002486. doi: 10.1371/journal.ppat.1002486. Epub 2012 Jan 12. PLoS Pathog. 2012. PMID: 22253598 Free PMC article.
-
A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma.Nat Med. 1995 Jul;1(7):707-8. doi: 10.1038/nm0795-707. Nat Med. 1995. PMID: 7585156
-
Soluble biomarkers of HIV-1-related systemic immune activation are associated with high plasma levels of growth factors implicated in the pathogenesis of Kaposi sarcoma in adults.Front Immunol. 2023 Sep 18;14:1216480. doi: 10.3389/fimmu.2023.1216480. eCollection 2023. Front Immunol. 2023. PMID: 37809059 Free PMC article.
-
Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease.Int J Infect Dis. 2005 Sep;9(5):239-50. doi: 10.1016/j.ijid.2005.02.004. Int J Infect Dis. 2005. PMID: 16095940 Review.
-
Infection of KSHV and Interaction with HIV: The Bad Romance.Adv Exp Med Biol. 2017;1018:237-251. doi: 10.1007/978-981-10-5765-6_15. Adv Exp Med Biol. 2017. PMID: 29052142 Review.
Cited by
-
Kaposi's sarcoma in a patient with pemphigus vulgaris mimicking exacerbation of pemphigus.Cancer Rep (Hoboken). 2023 May;6(5):e1815. doi: 10.1002/cnr2.1815. Epub 2023 Mar 31. Cancer Rep (Hoboken). 2023. PMID: 37002662 Free PMC article.
-
The Role of Killer Ig-like Receptors in Diseases from A to Z.Int J Mol Sci. 2025 Mar 31;26(7):3242. doi: 10.3390/ijms26073242. Int J Mol Sci. 2025. PMID: 40244151 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical